Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study).

Yunpeng YangTing ZhouXiaozhong ChenJingao LiJianji PanXiaohui HeLizhu LinYing-Rui ShiWeineng FengJianping XiongKunyu YangQitao YuQunling ZhangDesheng HuYan SunGuangyuan HuPing LiLiangfang ShenQin LinBen ZhangXiao QuJianjun ZouLi ZhangWenfeng FangYuanyuan Zhao

Published in: Journal for immunotherapy of cancer (2022)

Camrelizumab had clinically meaningful antitumor activity in patients with recurrent or metastatic NPC. The composition of both MHC-II+ cell density and PD-L1 expression could result in better patient selection.

Keyphrases

squamous cell carcinoma
small cell lung cancer
single cell
case report
cell therapy
newly diagnosed
mesenchymal stem cells